Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, non-comparative, multicenter, open-label, phase 2 study of Tarceva (Erlotinib) alone and of Tarceva plus VELCADE (bortezomib) for injection in patients with relapsed or refractory, locally advanced or metastatic non-small cell lung cancer.

Next Previous
X
Search
Trial Profile

A randomized, non-comparative, multicenter, open-label, phase 2 study of Tarceva (Erlotinib) alone and of Tarceva plus VELCADE (bortezomib) for injection in patients with relapsed or refractory, locally advanced or metastatic non-small cell lung cancer.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Takeda Oncology

    • Most Recent Events

    • 16 Feb 2011 Actual end date (1 Aug 2007) added as reported by ClinicalTrials.gov.
    • 01 Aug 2009 Results have been reported in the Journal of Thoracic Oncology.
    • 05 Jun 2007 Results have been published (1078763).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top